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An African loss-of-function 
CACNA1C variant p.T1787M 
associated with a risk of ventricular 
fibrillation
Malorie Blancard  1,2, Amal Debbiche1,2, Koichi Kato1,2, Christelle Cardin3, Guichard Sabrina4, 
Estelle Gandjbakhch1,2,5, Vincent Probst6, Michel Haissaguerre7,8, Fabrice Extramiana9, 
Mélèze Hocini7,8, Geoffroy Olivier10, Antoine Leenhardt  9, Pascale Guicheney  1,2 & Jean-
Sébastien Rougier  4
Calcium regulation plays a central role in cardiac function. Several variants in the calcium channel 
Cav1.2 have been implicated in arrhythmic syndromes. We screened patients with Brugada syndrome, 
short QT syndrome, early repolarisation syndrome, and idiopathic ventricular fibrillation to determine 
the frequency and pathogenicity of Cav1.2 variants. Cav1.2 related genes, CACNA1C, CACNB2 and 
CACNA2D1, were screened in 65 probands. Missense variants were introduced in the Cav1.2 alpha 
subunit plasmid by mutagenesis to assess their pathogenicity using patch clamp approaches. Six 
missense variants were identified in CACNA1C in five individuals. Five of them, A1648T, A1689T, 
G1795R, R1973Q, C1992F, showed no major alterations of the channel function. The sixth C-terminal 
variant, Cavα1c-T1787M, present mostly in the African population, was identified in two patients 
with resuscitated cardiac arrest. The first patient originated from Cameroon and the second was 
an inhabitant of La Reunion Island with idiopathic ventricular fibrillation originating from Purkinje 
tissues. Patch-clamp analysis revealed that Cavα1c-T1787M reduces the calcium and barium currents by 
increasing the auto-inhibition mediated by the C-terminal part and increases the voltage-dependent 
inhibition. We identified a loss-of-function variant, Cavα1c-T1787M, present in 0.8% of the African 
population, as a new risk factor for ventricular arrhythmia.
Cardiac channelopathies are genetic disorders associated with an increased risk of ventricular arrhythmia and 
sudden death (SD) in young individuals with a structurally normal heart. They include long QT syndrome 
(LQTS), Brugada syndrome (BrS) as well as other more rare diseases such as short QT syndrome (SQTS), early 
repolarisation syndrome (ERS), idiopathic ventricular fibrillation (IVF) and short-coupled torsades de pointes 
(scTdP)1. An important aspect of arrhythmia pathophysiology in these syndromes is the precise handling of 
cytoplasmic calcium concentration during the excitation-contraction (EC) coupling. One the most important 
effectors of this EC coupling is the L-type voltage-gated calcium channel Cav1.2 the main isoform expressed in 
ventricular cardiomyocytes. Its activation leads to an inward calcium current counterbalancing potassium out-
ward current and (1) hence contributes to action potential plateau phase and (2) triggers the calcium-induced 
calcium-release phenomenon leading to the rapid increase of cytosolic calcium concentration and the contraction 
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of cardiomyocytes2. Slight alterations in the calcium concentration during EC coupling could exert a great impact 
on arrhythmia vulnerability3.
Cav1.2 is a multi-subunit complex composed of a pore-forming subunit Cavα1c, and auxiliary subunits includ-
ing Cavβ2, and Cavα2δ14. Cavβ2 and Cavα2δ1, encoded by the CACNB2 and CACNA2D1 genes, respectively, regu-
late the gating properties and Cav1.2 trafficking5–8. The Cavβ2 subunit binds to Cavα1c DI-DII loop and promotes 
the cell surface density of Cav1.2 channels by preventing their degradation by the ubiquitin/proteasome system9,10. 
Co-expression of the Cavα2δ auxiliary subunit with Cavβ increases the calcium current and hyperpolarises the 
voltage of Cav1.2 activation11. Cavα1c, encoded by the CACNA1C gene, comprises four transmembrane domains 
(DI to DIV) connected by cytoplasmic loops and a large intracellular C-terminal domain. The C-terminal part 
is a major site of regulation of Cav1.2 channel, not only because it is the target site for many regulatory proteins 
but also due to the auto-inhibition activity of its distal C-terminal part (DCT). In vivo, most of the Cavα1c sub-
unit (80%) is cleaved at position 1770, releasing the DCT which acts as an auto-inhibitor peptide on Cav1.2 
via its non-covalent interaction with the proximal C-terminal (PCT) part12,13. Interestingly, despite the fact that 
the non-cleaved and the cleaved DCT have been shown to promote an auto-inhibitory effect on the calcium 
current (ICa), Hulme et al. showed that the cleaved DCT has a stronger auto-inhibitory effect on ICa than the 
non-cleaved one12. Knock-in mice expressing Cavα1c with a deleted DCT present perinatal mortality due to heart 
failure emphasises the fact that the DCT part of L-type calcium channel is primordial for normal cardiac devel-
opment and function14,15. In addition to the loop between DI and DII of Cavα1c which is known to be crucial 
for the channel inactivation gate, Brunet et al. showed that the auto-inhibitory complex could also increase the 
voltage-dependent inactivation of Cav1.2, further decreasing the calcium influx16,17. The non-covalent interac-
tion between the PCT and the DCT leading to the decrease of ICa has been shown to be calcium-dependent and 
modulated by calmodulin (CaM)13. In presence of low intracellular calcium, the interaction between the PCT 
and DCT will lead to a decrease of the open probability of Cav1.2. The increase in cytoplasmic calcium will allow 
the complex Ca2+-CaM to interact with the CDD domain localised at the DCT and the IQ and pre-IQ domain 
from the PCT. This interaction will disrupt the PCT-DCT complex and relieve the auto-inhibition leading to an 
increase of ICa13.
CACNA1C was the first gene involved in a multisystem disorder called Timothy syndrome (TS)18. Functional 
analysis of TS variants highlighted two different mechanisms triggering the severe QT interval prolongation and 
lethal arrhythmia observed in these patients. Missense variants localised at the C-terminal end of DI-S6 induce 
a nearly complete loss of Cav1.2 voltage-dependent inactivation (VDI) and prolongation of the plateau phase 
of cardiac action potential while others variants identified in the DIII-DIV loop induced a gain-of-function by 
increasing the “window” current19. Gain-of-function Cavα1c variants were also identified in the DI-DII loop in 
non-syndromic LQTS patients through an increase in channel surface membrane expression20. Furthermore, 
loss-of-function variants often associated with a shortening of the plateau phase of the action potential in the 
three Cav1.2 subunits have been reported in patients with BrS with or without short QT21,22, ERS23, SQTS24, and 
sudden unexplained death in the young (SUDY)22,25,26. Different molecular mechanisms were described, such 
as reduced current density due to impaired channel trafficking for the Cavα1c-A39V21, activation or inactivation 
curve shifts for Cavβ2b-S481L21 and SQTS-Cavα2δ1-S755T24 or a marked increase in Cav1.2 inactivation rate for 
Cavβ2b-T11I27. These variants have been associated with phase 2 re-entry28,29 or focal activation/re-entry from/
within the Purkinje fibres30. However, the fact that rare heterozygous missense variants were also present in the 
healthy populations questioned the implication of variants with experimentally unconfirmed pathogenicity in 
these diseases31,32.
Thus, there is a clear need to explore the function of new Cav1.2 variants to gain a better understanding of the 
link between these variants and life-threatening ventricular arrhythmias. As a result, we sought to identify new 
variants of Cav1.2 genes in a cohort of 65 patients, affected by inherited arrhythmia syndrome potentially related 
to calcium handling and to elucidate their functional consequences.
Results
We screened the genes encoding the three subunits of Cav1.2, CACNA1C, CACNB2, and CACNA2D1 in 65 
patients with BrS, SQTS, ERS, IVF or scTdP patients. Among them, 47 (72%) had syncopes or cardiac arrest 
(43%) and, 21 had a familial history of syncope or SD (32%) (Table 1).
In addition to frequent polymorphisms (MAF > 1% in all populations), we identified a number of less fre-
quent missense variants of unknown significance (VUS) in the coding sequence of CACNA1C in patients affected 
by BrS, ERS or IVF. No variants were found in CACNB2 or CACNA2D1. We performed functional analyses of 
missense variants identified in the patients described below.
Patients and variants. Six CACNA1C variants were found in 5 patients (7.7%). Case 1: This man had an 
aborted SD at the age of 27 when playing soccer (Fig. 1A). All investigations were negative (Holter recording, 
MRI, coronary angiography, isoprenaline and ajmaline tests). The only aetiology found was an early repolar-
isation pattern in ECG inferior and lateral leads during the days after resuscitation (Fig. 2A,B). An automatic 
implantable cardio defibrillator (ICD) was implanted, and the patient experienced only very short sustained epi-
sodes of ventricular tachycardia that were not treated by the ICD during the following years. This patient, of 
Franco-Cameroonian origin, was part of a family with no other cardiac events. He was the only one with an ERS 
pattern and carrying a missense variant, p.Thr1787Met (Cavα1c-T1787M), localised in the C-terminal domain of 
Cavα1c calcium channel subunit (Fig. 1A and Supplementary Fig. S1C). The threonine residue at position 1787 is 
conserved through evolution among many species but is replaced by an alanine in horse and dog (Supplementary 
Fig. S2). The methionine substitution is considered as probably damaging according to Polyphen2 and the DANN 
Score. Cavα1c-T1787M has a minor allele frequency (MAF) of 0.12% according to ExAC database, but it was in 
fact mostly found in Africans, both in the heterozygous state in 113 of 3565 individuals, and in the homozygous 
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state in one subject (Table 2). As expected, it was absent from our Caucasian control population. Another variant, 
p.Gly1795Arg (G1795R), with a higher frequency (MAF = 0.54% according to ExAC) was also found in this sub-
ject. His healthy son only carried the latter variant, which is frequent in Africans (MAF = 7%), and is therefore 
considered as likely benign (Supplementary Fig. S1D).
Case 2: This woman had syncope at rest at the age of 43 years, followed by a resuscitated cardiac arrest during 
hospitalisation with the detection of scTdP originating from Purkinje fibres (Fig. 2C). The origins of her family 
are from La Reunion, where four SD of unknown aetiology occurred in young children (Fig. 1B). A coronary 
angiography and echocardiography excluded ischaemic or structural abnormalities. She received an ICD and a 
verapamil treatment of 240 mg twice a day. A right ventricular scintigraphy performed at the age of 49 did not 
reveal any signs of arrhythmogenic right ventricular cardiomyopathy (ARVC). During the follow-up period, sev-
eral asymptomatic non-sustained ventricular tachycardia events were recorded by the ICD, beginning with pre-
mature ventricular beats (PVB) with short coupling intervals (320 ms) (Fig. 2D). When she skipped her verapamil 
treatment, non-sustained ventricular tachycardia with a feeling of faintness and palpitation was also recorded. 
Electrocardiographic screening of the other family members did not show any abnormalities.
The proband carried two variants in CACNA1C, Cavα1c-T1787M and p.Cys1992Phe (C1992F) (Fig. 1B, 
Supplementary Fig. S1C,F). The first variant, Cavα1c-T1787M, was the same as in the previous family. The sec-
ond CACNA1C variant, C1992F, was found in East Asians (7/8536 alleles) and Africans (5/8536 alleles) with an 
overall MAF of 0.01% in ExAC. The cysteine residue at position 1992 in Cavα1c is highly conserved among species 
(Supplementary Fig. S2) and its substitution with a phenylalanine is considered as probably damaging according 
to Polyphen2, Mutation Taster and the DANN Score (Table 2). This variant is also located in the C-terminal 
region of the channel subunit. By genotyping some family members, we found that the proband was the only 
BrS SQTS ERS IVF scTdP
Probands (male) 25 (22) 7 (7) 7 (7) 7 (4) 19 (8)
Symptomatic 12 (48%) 3 (42%) 7 (100%) 7 (100%) 19 (100%)
Resuscitated cardiac arrest 3 (12%) 1 (14%) 6 (86%) 7 (100%) 11 (58%)
Mean age at first symptoms (years) ±SD 38.8 ± 14.2 25.3 ± 3.8 33.8 ± 4.3 46.1 ± 12.6 32.9 ± 10.9
Mean age at clinical diagnosis (years) ±SD 45.0 ± 12.4 31.1 ± 5.7 37.8 ± 3.2 49.7 ± 10.6 33.7 ± 10.1
Family history of syncopes or SD 7 (28%) 6 (71%) 1 (14%) 1 (14%) 6 (32%)
Spontaneous BrS type 1 pattern 15 (62.5%) 0 0 0 0
QTc (ms) 364 ± 3 332 ± 3 384 ± 10 409 ± 20 403 ± 31
Table 1. Clinical characteristics of the patient cohort.
Figure 1. Family pedigrees of Cases 1 to 5 (A–E) with the members carrying CACNA1C variants. The probands 
are indicated by an arrow. Males are represented by squares, females by circles, affected subjects by filled 
symbols, and healthy subjects by open symbols. Cavα1c missense variants or their absence (no) are indicated 
below each subject that has been genotyped.
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carrier of two variants in Cav1.2 calcium channel subunits; other family members who have been genotyped were 
only carriers of one of these two variants.
Three additional VUS were identified in the proband: p.Leu618Phe (L618F) in the cardiac sodium chan-
nel (SCN5A, NM_198056, c.1852C > T) with an overall MAF of 0.057%, and two variants in desmosomal 
proteins known to be associated with ARVC: p.Asn1865Trp (N1865W) in desmoplakin (DSP, NM_004415.2, 
c.5593 A > T), with a frequency of 0.051%, and p.Val842Ile (V842I) in plakophilin 2 (PKP2, NM_004572, 
c.2524 G > A), with an MAF of 0.0049% (Supplementary Fig. S3).
Case 3: This patient comes from a French family where several SD occurred in young adults (Fig. 1C). She had 
a resuscitated cardiac arrest after lunch and her ECG showed scTdP, possibly originating from Purkinje tissue. Her 
own mother had died at the age of 25 during the night. Her daughter also had ventricular fibrillation originating 
from the Purkinje network and numerous scPVB episodes at the age of 15 years. An ICD was implanted and 
catheter ablation performed. A CACNA1C missense variant, p.Ala1648Thr (A1648T), was detected in the affected 
mother and daughter (Fig. 1C and Supplementary Fig. 1A). The alanine residue at position 1648 is located in a 
well conserved region of the protein (Supplementary Fig. S2) and its substitution with a threonine was considered 
as possibly damaging according to several prediction tools (Table 2). The variant was only found in 10 Europeans 
(10/70496 alleles) with an overall frequency of 0.01% according to the ExAC database.
Case 4: This French patient presented an aborted SD at the age of 21 during exercise, without any aetiology. 
Echocardiography and cardiac MRI did not show any morphological abnormality, and a stress test did not show 
any argument in favour of a catecholaminergic tachycardia. His basal ECG was normal and ajmaline test was 
negative. The patient was implanted with an ICD without other medical treatment. During the follow-up, the ICD 
delivered several appropriate shocks on ventricular tachycardia. At the age of 26 years, a second ajmaline test was 
performed and was positive. There was no family history of syncope or cardiomyopathy. A CACNA1C variant 
was identified, p.Ala1689Thr (A1689T), affecting an alanine that is well conserved during evolution (Fig. 1D, 
Supplementary Figs S1B and S2). This variant was absent from our Caucasian control population and considered 
as possibly damaging according to Polyphen2, Mutation Taster and the DANN Score (Table 2).
Case 5: Two sisters originating from La Reunion Island were diagnosed with IVF associated with scTdP. Their 
great aunt, who had episodes of syncope, died suddenly at age 50. The first sister had two consecutive syncopal 
episodes and resuscitated cardiac arrest at age 39 with scTDP (300 msec). Subsequently, she was implanted with 
an ICD. She experienced an appropriate shock one year after implantation and presented an electrical storm three 
years after. Her sister had a first syncope during fever at 36 and then later complained of palpitations. She pre-
sented scPVB (320 msec) at ECG and scTdP (260 msec) was detected on Holter recording during palpitations. She 
was implanted with an ICD at age 45, but never experienced appropriate shocks. The two sisters were treated with 
Figure 2. Electrocardiograms of Cases 1 and 2. Case 1, (A) just after reanimation showing early repolarisation 
pattern, (B) 5 years later. Case 2, (C) short-coupled torsades de pointes, (D) short-coupled premature 
ventricular beats.
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verapamil. They both carry the same CACNA1C variant, p.Arg1973Gln (R1973Q) (Fig. 1E and Supplementary 
Fig. S1E). The arginine residue at position 1973 of Cavα1c is highly conserved among species (Supplementary 
Fig. S2) and is located within the Cavα1c C-terminal domain. The glutamine substitution was considered as prob-
ably pathogenic according to Polyphen2, Mutation Taster and the DANN Score. However, this variant was present 
in all ethnic populations in the ExAC database with an overall MAF of 0.36% (Table 2).
Loss-of-function of the Cavα1c-T1787M variant in CACNA1C. The six C-terminal variants, A1648T, 
A1689T, T1787M, G1795R, R1973Q, and C1992F were introduced by mutagenesis in the Cavα1c subunit. 
Functional patch-clamp studies showed that, despite a slight shift in steady-state inactivation for the variants 
A1648T and A1689T in the presence of extracellular calcium, only the Cavα1c-T1787M variant leads to a decrease 
in ICa and barium current (IBa) compared to the wild-type (WT). No major alteration of the main biophysical 
properties was found for Cavα1c-T1787M (steady-state activation and inactivation) (Figs 3–4, Supplementary 
Figs S4–S9, Tables 3 and 4). Immunoblotting studies showed no alterations in calcium channel subunit expression 
after the over-expression of Cavα1c-T1787M (Supplementary Fig. S10A). Moreover, biotinylation of cell surface 
proteins showed that the surface expression of WT or Cavα1c-T1787M was not significantly different (113 ± 11 vs 
94 ± 17%, respectively, n = 3 experiments) (Supplementary Fig. S10B).
Interestingly, while the calcium-dependent inactivation (CDI) was not altered by the different variants 
(Fig. 3D, Supplementary Fig. S11), the voltage-dependent inactivation (VDI) was significantly increased in the 
presence of the Cavα1c-T1787M variant only (Fig. 4D, Supplementary Fig. S12).
The inhibition mediated by the cleaved CT part on the CT-cleaved Cavα1c construct is stronger 
when the Cavα1c-T1787M variant is present. Since no modification of the main biophysical properties 
of the Cavα1c-T1787M and a normal expression at the membrane were found, another mechanism should explain 
the observed reduced current density. Interestingly, the variant is localised close to the in vivo proteolytic cleavage 
site (A1770) at the beginning of the cleaved C-terminal (cleaved CT) involved in the auto-inhibition process of 
Cav1.2 channel (Fig. 5). The auto-inhibition mechanism is mediated by the interaction of the proximal C-terminal 
regulatory domain (PCRD) localised in the PCT with the distal C-terminal regulatory domain (DCRD) present 
in the DCT (Fig. 5). This interaction has also been shown to be modulated by CaM via its interaction with the 
CaM-competitive domain (CCD) and the pre-IQ and IQ motif (see introduction) (Fig. 5).
To investigate whether Cavα1c-T1787M could modulate this inhibition, a truncated construct at the in-vivo 
cleavage site has been generated (A1770*) (Fig. 5). As already published, the current produced by the A1770* 
truncated form is greater than that of the WT channel (WT: 34 ± 4 pA/pF (n = 36) and A1770*: 100 ± 15 pA/pF 
(n = 21); p < 0.05)12. Barium currents mediated by this CT-cleaved Cavα1c form were decreased by 36 ± 9% when 
co-expressed with the WT-cleaved CT part with a significant shift of the steady-state activation curve (Fig. 6 and 
Table 3). However, when co-expressed with the cleaved CT part harbouring the Cavα1c-T1787M variant, IBa was 
further decreased without biophysical property alterations compared to the WT-cleaved CT, suggesting that the 
presence of the variant increases the auto inhibition effect (−38 ± 10%, CT-cleaved Cavα1c + WT-cleaved CT vs 
CT-cleaved Cavα1c + T1787M-cleaved CT; p < 0.05) (Fig. 6 and Table 4).
Discussion
Calcium influx via the Cav1.2 L-type calcium channel provides a multi-functional signal that triggers muscle 
contraction, controls action potential and regulates gene expression33. Therefore, a dysregulation of the calcium 
channel function may lead to cardiac rhythm disorders. A limited number of Cav1.2 variants have been studied; 
thus, the extent of their potential role remains unknown and requires validation by functional studies19. Some 
mutations in the CACNA1C gene were first identified in Timothy syndrome, causing extreme QT prolongation 
and SD18. The role of these gain-of-function mutations of Cav1.2 in ventricular repolarisation prolongation was 
Case n° 1 and 2 1 (ERS) 2 (scTdP) 3 (scTdP) 4 (BrS) 5 (scTdP)
Genomic location 
Chr12 (GRCh38) 2679712 2679735 2688637 2677207 2677841 2688580
NM_000719
c.DNA variation c.5360 C > T c.5383 G > A c.5975 G > T c.4942 G > A c.5065 G > A c.5918 G > A
protein variation T1787M G1795R C1992F A1648T A1689T R1973Q
NM_199460
c.DNA variation c.5504 C > T c.5527 G > A c.6224 G > T c.5086 G > A c.5209 G > A c.6167 G > A
protein variation T1835M G1843R C2075F A1696T A1737T R2056Q
MAF
ExAC (All) (%) 0.12 0.54 0.01 0.008 0.0031 0.36
ExAC (Africans) (%) 1.61 7.03 0.05 0 0 0.02
ISB Kaviar 3 (%) 0.12 0.39 0.008 0.006 0.0026 0.31
Pathogenicity
Polyphen 2 Probably damaging: 0.993 Benign: 0.001
Probably damaging: 
0.998 Possibly damaging: 0.948 Possibly damaging: 0.949
Probably damaging: 
0.977
Mutation Taster Polymorphism Polymorphism Disease causing Disease causing Disease causing Disease causing
ClinVar Benign- Likely benign
Benign- Likely 
benign Uncertain significance Uncertain significance Uncertain significance
Conflicting 
interpretations of 
pathogenicity
DANN Score 0.9966 0.9892 0.9872 0.8767 0.9982 0.8254
Table 2. CACNA1C variants.
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confirmed by the discovery of several other mutations in non-syndromic sporadic and familial LQTS cases20,34. 
On the other hand, several missense variants in the Cav1.2 subunits were reported as loss-of-function mutations 
in BrS, SQTS, ERS and SUDY patients21,22,24–26. The low penetrance of these variants suggests a complex genetic 
inheritance with an accumulation of several genetic risk factors of variable frequencies35.
In this study, we aimed to identify variants in the three genes encoding Cav1.2 subunits in patients affected 
with various kinds of arrhythmia disorders (BrS, SQTS, ERS, IVF and scTdP). We reported six missense variants 
in CACNA1C, one in a BrS patient, and the five others in patients with ERS and IVF. Our patch-clamp exper-
iments revealed that, among the variants found in this study, the Cavα1c-T1787M variant was the only Cavα1c 
variant to cause a significant reduction in ICa and IBa. Barium current recordings also showed an increase in VDI 
for the Cavα1c-T1787M variant compared to WT. Since ICa is involved in the cardiac action potential plateau 
phase, an increase in Cav1.2 VDI combined with a decrease in ICa would lead to a shorter plateau phase and thus a 
shorter action potential. Interestingly, the QTc intervals of Cases 1 and 2 were relatively short (358 ms and 380 ms, 
respectively). Several other mutations (E1829_Q1833dup, Q1916R, V2014I) linked to BrS or ERS patients have 
been reported in this region, flanked by the PCRD and the DCRD, also leading to a loss-of-function (Fig. 5)21–23. 
The E1829_Q1833dup, close to the Cavα1c-T1787M variant, induced a drastic decrease in the calcium current 
amplitude. Unfortunately, the molecular mechanism of this loss-of-function is not known.
The C-terminal part of Cavα1c subunit serves as a scaffold for the targeting and localisation of signalling 
molecules including calmodulin36, calmodulin-dependent protein kinase II37, PKA and its anchoring proteins 
AKAP1538. In addition, this C-terminal domain has also been shown to be cleaved in vivo12.This mechanism will 
allow the DCRD, from the cleaved CT, to non-covalently bind to the PCRD of the CT-cleaved Cavα1c in order to 
form a complex12. Finally, this complex has been shown to decrease the open probability and modulate the cou-
pled channel gating of Cav1.2 channel leading to a global decrease of ICa12,39,40.
Interestingly, experiments performed in this study using the CT-cleaved Cavα1c construct suggest a potential 
role for the Cavα1c-T1787M variant in the auto-inhibitory effect. The fact that the decrease in IBa observed in 
presence of WT-cleaved CT is amplified when the mutation is introduced in this cleaved CT suggests that the 
Cavα1c-T1787M variant could potentially increase the interactions between the PCRD and the DCRD. Stronger 
interaction such as this could lead to an absence of gating coupling between Cav1.2 channels, as proposed by 
Navedo and co-workers, and/or a greater inhibition of the barium current due to the auto-inhibitory mechanism 
suggested by Wei and colleagues39,40. Nevertheless, further experiments should be performed to challenge these 
hypotheses.
Figure 3. Loss-of-function of Cavα1c-T1787M variant: calcium currents (ICa). (A) Representative whole-
cell ICa traces showing the decrease of current density with the Cavα1c-T1787M variant compare to WT. (B) 
Current-voltage relationships in cells transfected with either WT (○) or Cavα1c-T1787M variants (●) of 
calcium channels (*p < 0.05). (C) Steady-state inactivation and activation curves of either WT (white symbol) 
or Cavα1c-T1787M variants (back symbol) of calcium channels showing no major alterations. (D) Calcium-
dependent inactivation (CDI) with either WT (○) or Cavα1c-T1787M variants (●) of calcium channels showing 
no alterations. The number of cells is indicated in parentheses.
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The fact that only the V1/2 for the steady-state inactivation of the A1648T and A1689T variants were signifi-
cantly shifted in the presence of extracellular calcium is surprising and could be due to an artefact of the analysis. 
In fact, the sigmoid curves calculated by the software do not always fit with the raw data points recorded. Based 
on these observations, and due to the fact that neither the peak current densities nor other biophysical parameters 
are altered, additional experiments are required to confirm these alterations.
Although we identified this pathogenic variant in two IVF patients, we did not find pathogenic variants 
responsible for BrS or SQTS in our cohort as previously reported, and two of the three variants identified in 
scTdP appeared to be non-functional polymorphisms. We identified six variants in CACNA1C, two of which, 
R1973Q and Cavα1c-T1787M, have already been reported by Burashnikov et al. in two BrS patients and one BrS 
patient, respectively22. The latter did not form part of those who underwent functional analyses22. Measures of 
evolutionary sequence conservation and allele frequency are widely used as indicators of the deleteriousness of 
protein variation but their predictive power is limited by statistical and biological factors41. Interestingly, among 
the identified variants, the five most conserved residues in Cav1.2 Cavα1c were non-pathogenic and our only 
pathogenic variant, Cavα1c-T1787M, was not perfectly conserved among all mammals and was found in 0.8% of 
Figure 4. Loss-of function of Cavα1c-T1787M variant: barium currents (IBa). (A) Representative whole-cell IBa 
traces showing the decrease of current density with the Cavα1c-T1787M variant compare to WT. (B) Current-
voltage relationships in cells transfected with either WT (○) or Cavα1c-T1787M variants (●) of calcium 
channels (*p < 0.05). (C) Steady-state inactivation and activation curves of either WT (white symbol) or Cavα1c-
T1787M variant (back symbol) of calcium channels showing no major alterations. (D) Voltage-dependent 
inactivation (VDI) with either WT (○) or Cavα1c-T1787M variant (●) of calcium channels showing an increase 
of the VDI (*p < 0.05 and **p < 0.01). The number of cells is indicated in parentheses.
Normalized maximum 
peak current Activation Steady-state inactivation
% V1/2 (mV) K V1/2 (mV) K
WT 100 ± 18 (19) 15.45 ± 1.64 (19) 7.92 ± 0.73 (19) −30.43 ± 1.05 (15) 12.96 ± 0.79 (15)
A1648T 128 ± 15 (5) 15.45 ± 2.29 (5) 8.41 ± 0.24 (5) −34.40 ± 1.56 (5)* 14.73 ± 0.70 (5)
A1689T 112 ± 46 (7) 12.84 ± 1.31 (7) 8.01 ± 0.22 (7) −24.11 ± 0.69 (7)* 13.61 ± 0.65 (7)
T1787M 48 ± 14 (6)* 11.86 ± 1.89 (6) 8.19 ± 0.31 (6) −29.90 ± 1.04 (15) 13.73 ± 0.67 (15)
G1795R 94 ± 54 (5) 11.68 ± 1.80 (5) 8.23 ± 0.63 (5) −25.73 ± 1.71 (7) 14.33 ± 0.67 (7)
R1973Q 135 ± 28 (6) 12.29 ± 0.97 (7) 7.87 ± 0.13 (7) −25.61 ± 1.29 (9) 13.21 ± 0.86 (9)
C1992F 109 ± 30 (6) 12.21 ± 1.04 (7) 7.94 ± 0.18 (7) −25.84 ± 1.64 (6) 12.69 ± 0.57 (6)
Table 3. Biophysical parameters of Cav1.2 variants with calcium. Activation and steady-state inactivation 
parameters (see material and methods) of WT and variants of Cav1.2 channels. In bold, values significantly 
different from WT (*p < 0.05). The number of cells is indicated in parentheses.
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Africans. Many deleterious variants do not show a strong conservation signature and conversely, strong conser-
vation does not necessarily mean that the variant has an effect on disease risk, which is consistent with our results. 
Due to the relatively high frequency in Africans, the Cavα1c-T1787M variant would initially have been excluded 
during exome sequencing data analysis according to classical criteria. Since it was found in two unrelated patients 
with ventricular fibrillation: Cases 1 and 2 originating from Cameroon and from La Reunion, an island of known 
mixed origin, we performed functional analysis. A strong association between early repolarisation pattern and/or 
sudden death was reported in several studies including Cameroonian patients42–44. As seen for a number of other 
ECG-derived traits, such as QT interval, an early repolarisation pattern is a heritable component45.
The results presented in this study suggest that the CACNA1C variant Cavα1c-T1787M is likely a potential new 
risk factor contributing to the development of ventricular arrhythmogenicity in Africans. The best-known African 
pro-arrhythmic variant is Nav1.5-S1103Y, which has a MAF of 13% in African Americans46–48. The Y1103 allele 
carriers have an inherent susceptibility to potentially lethal arrhythmias, and are frequent in cohorts of patients 
with SD49 and Sudden Infant Death Syndrome48,50. Additional factors, such as other genetic variants51, medica-
tions46, heart failure associated with a reduced ejection fraction52, and hypokalemia associated with diuretic use53 
can contribute to fatal arrhythmias. Interestingly, case 1 is also a heterozygous carrier of the Nav1.5-S1103Y variant. 
The association of the two variants Cavα1c-T1787M and Nav1.5-S1103Y might contribute to the patient phenotype.
In addition to the Cavα1c-T1787M, Case 2 inherited a variant in the sodium channel, L618F, and two variants 
in desmosomal proteins, N1865Y in desmoplakin and V842I in plakophilin 2 from her mother. The leucine 
residue at position 618 is located in the I-II linker domain of the cardiac Na+ channel, next to L619F muta-
tion, reported in a LQT3 child and associated with a defective inactivation, a faster recovery and an increase in 
Normalized maximum 
peak current Activation Steady-state inactivation
% V1/2 (mV) K V1/2 (mV) K
WT 100 ± 10 (46) −7.49 ± 0.42 (35) 6.18 ± 0.13 (35) −35.74 ± 1.01 (43) 12.24 ± 0.96 (43)
A1648T 92 ± 20 (10) −6.53 ± 0.73 (11) 5.83 ± 0.20 (11) −37.93 ± 1.45 (9) 11.68 ± 0.24 (9)
A1689T 94 ± 25 (10) −9.14 ± 0.80 (5) 6.06 ± 0.11 (5) −33.67 ± 1.20 (6) 7.54 ± 0.40 (6)
T1787M 28 ± 16 (8)* −5.53 ± 1.63 (15) 5.84 ± 0.45 (15) −32.93 ± 2.50 (10) 9.18 ± 0.80 (10)
G1795R 93 ± 7 (8) −6.35 ± 0.90 (10) 6.08 ± 0.18 (10) −37.35 ± 1.59 (10) 12.43 ± 0.63 (10)
R1973Q 90 ± 14 (20) −7.31 ± 0.46 (18) 6.09 ± 0.13 (18) −37.60 ± 0.76 (19) 11.77 ± 0.31 (19)
C1992F 97 ± 12 (19) −6.23 ± 0.73 (17) 5.93 ± 0.12 (17) −35.70 ± 0.74 (16) 12.67 ± 0.39 (16)
A1770* 100 ± 10 (21) −12.29 ± 0.75 (20) 5.61 ± 0.16 (20) −38.77 ± 1.13 (21) 9.96 ± 0.42 (21)
A1770*/WT 64 ± 9 (24) −9.30 ± 0.70 (24) 5.94 ± 0.16 (24) −39.31 ± 0.72 (24) 10.32 ± 0.41 (24)
A1770*/T1787M 39 ± 6 (23)* −9.39 ± 0.88 23) 6.18 ± 0.18 (23) −38.61 ± 1.22 (23) 10.95 ± 0.47 (23)
Table 4. Biophysical parameters of Cav1.2 variants with barium. Activation and steady-state inactivation 
parameters (see material and methods) of WT, variants, and truncated constructs of Cav1.2 channel. In bold: 
WT vs Cavα1c-T1787M and underlined A1770*/WT vs A1770*/T1787M (*p < 0.05). The number of cells is 
indicated in parentheses.
Figure 5. Scheme of the C-terminal part of the voltage-gated calcium channel. Schematic representation 
modified from Lyu et al. 2017 showing the C-terminal domain of Cavα1c with EF-hand like region (EF), pre-IQ, 
IQ, PCRD, DCRD, and CaM-competitive domain (CCD)62. The interaction between the PCRD and the DCRD 
forming the auto-inhibitory complex and the different sites of interaction with CaM (pre-IQ, IQ, and CCD) are 
depicted with dashed arrows. Asterisks correspond to human loss-of-function variants (present data, red)22. The 
in vivo cleavage site by proteolysis correspond to 1764-NANINNANN-1772 in human. The scissors show the 
position of the truncation of Cavα1c subunit performed in this study (A1770, 1800 in rabbit).
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window current54. These two adjacent leucines are conserved in four other sodium channels (Nav1.1, Nav1.2, 
Nav1.6, Nav1.7), and the variant L618F is mostly found in Africans (MAF = 0.64%). A previous study reported 
no change in window current and late sodium current for L618F in the background of the hH1-Q1077 isoform55. 
Nevertheless, since variant alterations may vary according to the isoform used in expression studies, we stud-
ied this variant again in the most abundant hH1a-Q1077del Nav1.5 isoform background47,56 and confirmed the 
benign effect of this variant (Supplementary Fig. S13). Accordingly, no QT prolongation was observed in the 
family members carrying this variant. As for the desmosomal protein variants, PKP2-V842I and DSP-N1865Y, 
these rare variants are both of unknown significance. They have never been reported and were found in 6/60,000 
and 1/60,000 subjects in the ExAC database. MRI did not diagnose any structural abnormalities in Case 2, nor in 
her sisters carrying one or two of these variants. Only the mother at the age of 72 showed a mild dilatation of the 
right ventricle. Interestingly, some PKP2 variants have been reported to locally modify sodium channel density at 
intercalated disks57, and the silencing of desmoplakin decreases connexin 43/Nav1.5 expression and sodium cur-
rent in HL1 cardiac muscle cell line58. The accumulation of all of these variants in a same subject may contribute 
to the ventricular hyperexcitability observed in Case 2.
Identifying the origin of cardiac channelopathies in patients with rare arrhythmias provides a unique oppor-
tunity to identify at risk surviving relatives and the possible prevention of future SD. This study underlined the 
hypothesis of a combinatory effect of several variants to explain the phenotype of the patients, especially Cases 1 
and 2. Indeed, the Cavα1c-T1787M variant may not be sufficient to cause the phenotype observed in patients, but 
like Nav1.5-S1103Y, it could play a role combined with additional risk factors.
Conclusions
Overall, this study shows that the Cavα1c-T1787M variant present in 0.8% of the African population was identi-
fied in two out of 65 patients (3.1%) with resuscitated cardiac arrest. This variant causes a potentially arrhythmo-
genic Cav1.2 loss-of-function.
Limitations of the study. Patch-clamp analysis of five of our variants did not show any abnormal Cav1.2 
activities. Nevertheless, based on the limitations due to the experimental model used in this investigation, we can-
not exclude that those variants could lead to abnormal calcium handling in native cardiomyocytes. In fact, in car-
diac cells, contrary to the TsA-201 cell line, Cav1.2 channels are mainly expressed in the T-tubule structure within 
macro-molecular complexes allowing specific regulation of the voltage-gated calcium channel59. Further investi-
gations using another model close to cardiomyocytes such as cardiomyocytes derived from induced pluripotent 
stem (iPS) cells from the patients could be an alternative to decipher whether those variants are pathogenic or not.
Material and Methods
Patients. The patient cohort consisted of probands originating from different countries with BrS, SQTS, 
ERS, IVF and scTdP according to the international consensus criteria1,60. Underlying structural heart disease 
was excluded by echocardiography. Laboratory tests excluded acute ischaemia and metabolic or electrolyte 
disturbances.
Figure 6. The IBa inhibition mediated by the cleaved CT part on the CT-cleaved Cavα1c construct is stronger 
when the Cavα1c-T1787M variant is present. (A) Representative raw traces of IBa density recorded in presence 
of CT-cleaved Cavα1c alone or with either WT or T1787M-cleaved CT part. (B) I-V relationships showing 
the effect mediated by T1787M variant on the CT-cleaved Cavα1c when introduced in the cleaved CT part 
(*p < 0.05: CT-cleaved Cavα1c + WT-cleaved CT vs CT-cleaved Cavα1c + T1787M-cleaved CT). The number of 
cells is indicated in parentheses.
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Symptomatic and asymptomatic BrS probands, displayed a BrS type-1 pattern on electrocardiogram (ECG) 
(ST segment elevation ≥2 mm in one or more right precordial leads), either spontaneously, or induced by a 
sodium blocker challenge test (ajmaline or flecainide). All were negative for mutations in SCN5A, SCN1B, SCN2B, 
SCN3B, KCNJ8, KCNE3, KCND3, and RANGRF.
SQTS probands had either QTc intervals inferior to 330 msec, or QTc between 330 and 360 msec with a family 
history of SD before the age of 40, or survival of VT/VF episode in absence of heart disease.
ERS was diagnosed in the presence of J-point elevation ≥1 mm in ≥2 contiguous inferior and/or lateral leads 
of a standard 12-lead ECG in patients with or without cardiac arrest from otherwise unexplained VF/polymor-
phic VT.
Twenty-six patients had syncopes with a normal ECG at rest and during exercise stress test. Seven of them 
had a resuscitated cardiac arrest and were diagnosed as IVF in absence of cardiac, respiratory, metabolic and 
toxicological aetiologies. Nineteen presented with scPVB or scTdP originating from Purkinje fibres confirmed by 
electrophysiological study and were classified as scTdP.
Blood samples were obtained after signed informed consent forms were collected for genetic analyses and 
upon approval of the local ethics committee of the Saint-Louis Hospital. The study was conducted according to 
the principles of the Helsinki Declaration.
CACNA1C, CACNB2 and CACNA2D1 analysis. Genomic DNA was extracted from peripheral blood leu-
kocytes according to standard procedures. The genes CACNA1C (NM_199460.3), CACNB2 (NM_000724.3), and 
CACNA2D1 (NM_000722.3) were first screened in 2012 in 47 patients using a high-resolution melt (HRM) anal-
ysis method in a real-time PCR thermocycler (LightCycler 480®, Roche Diagnostics®). Primers were designed 
according to HRM specifications and permitted the amplification of all exons and splice junctions (available 
upon request). Results were analysed using the gene-scanning module of the LightCycler 480® software (Roche 
Diagnostics®). When a new variant was identified, the PCR product was purified and sequenced with the Big 
Dye Terminator v.3.1 kit (Applied Biosystems®). Sequencing was performed on the ABI PRISM 3730 automatic 
DNA sequencer (Applied Biosystems®). Variants were identified by visual inspection of the sequence with Codon 
Code Aligner® software (4.1.1 version). Then, the frequency of novel non-synonymous variants was evaluated by 
screening 300 Caucasian and 100 North African unrelated healthy controls.
In addition, a whole exome sequencing (WES) was performed in 2015 by IntegraGen (Evry, France) for 18 
probands presenting IVF associated with scPVB or scTdP. Genomic DNA were fragmented by sonication and 
purified to yield fragments of 150–200 bp. Paired-end adaptor oligonucleotides from the NEBNext Direct kit 
(New England Biolabs) were ligated on repaired, tailed fragments and then purified and enriched by 8 PCR 
cycles. From these purified libraries, 1200 ng were then hybridised to the SureSelect oligo probe capture library 
(SureSelect XT Clinical Research Exome −54 Mb, Agilent) for 72 hours. After hybridisation, washing, and elu-
tion, the eluted fraction was PCR-amplified with 9 cycles, purified and quantified by QPCR to obtain sufficient 
DNA template for downstream applications. Each eluted-enriched DNA sample was then sequenced on an 
Illumina HiSeq4000 as paired-end 75b reads. Bioinformatic analyses were performed by IntegraGen. Reads were 
aligned with human genome assembly GRch37. The variants were filtered using IntegraGen ERIS platform.
The prediction of the amino acid substitution effect on protein structure and function was 
assessed using different prediction tools including Polyphen2, Mutation Taster, ClinVar and the 
DANN Score61. The variant allele frequencies in population of various origins were obtained from the 
Exome Aggregation Consortium database (ExAC) (http://exac.broadinstitute.org/) and from the cat-
alogue of human genomic variation, ISB release Kaviar (https://www.systemsbiology.org/research/
isb-releases-kaviar-worlds-largest-public-catalog-of-human-genomic-variation/). Variants were numbered in 
the text and figures according to the sequence NM_000719.6 as most of the previous published variants.
Cav1.2 subunit expression vectors and mutagenesis. Truncated and WT rabbit Cav1.2 cardiac iso-
form Cavα1c (NM_001136522), Cavβ2 (NM_001082396.1) and Cavα2δ1 (NM_001082276) complementary DNAs 
(cDNAs) subcloned into pCARDHE, pBH17 and pCA1S, respectively, were gifts from Dr G.S. Pitt (Department 
of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC, USA). Mutants were gen-
erated using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, USA) according to the manufac-
turer’s instructions. Primers designed for mutagenesis are available upon request. All plasmids were checked by 
sequencing.
Transfections. T25 cm2 flasks of TsA-201 cells at 80% confluency were transiently co-transfected using 
X-tremeGene 9® mix reagent (Roche Diagnostics, IN, USA) with 0.7 µg of each subunit of voltage-gated calcium 
channel (Cavα1c, Cavβ2b and Cavα2δ1 subunits, ratio1:1:1). All transfections included 0.2 µg of cDNA encoding 
CD8 antigen and 0.1 µg of cDNA encoding GFP as a reporter gene. For the co-expression assays using cleaved 
CT constructs, the fragment coding for the C-terminal part has been introduce in pIRES vector co-expressing 
CD8. For patch clamp experiments, anti-CD8 beads (Dynal®, Oslo, Norway) were used. Only cells decorated with 
anti-CD8 beads that were concomitantly green (GFP) were analysed.
Electrophysiology. Whole-cell currents were measured at room temperature (22–23 °C) using a VE-2 
amplifier (Alembic Instrument, USA). The internal pipette solution was composed of (in mmol/L) 60 CsCl, 70 
Cs-aspartate, 1 MgCl2, 10 HEPES, 11 EGTA and 5 Mg-ATP, pH 7.2, with CsOH. The external solution con-
tained (in mmol/L) 130 NaCl, 5.6 CsCl, 5 BaCl2 or 20 mM CaCl2, 1 MgCl2, 10 HEPES and 11 D-glucose, pH 
7.4, with NaOH. Data were analysed using pClamp software, version 10.2 (Axon Instruments, Union City, 
California, USA). Calcium and barium current densities (pA/pF) were calculated by dividing the peak current 
www.nature.com/scientificreports/
1 1Scientific REPORTs |  (2018) 8:14619  | DOI:10.1038/s41598-018-32867-4
by the cell capacitance. Activation curves and steady-state inactivation curves were fitted with the following 
single Boltzmann equation: y = 1/(1 + exp [(Vh − V50)/k]), in which y is the normalised conductance or peak 
current at a given holding potential (Vh); V50 is the voltage at which half of the channels are activated (V50, 
act) or inactivated (V50, inact) respectively, and k is the slope factor. Calcium-dependent inactivation (CDI) and 
voltage-dependent inactivation (VDI) in presence of extracellular calcium or barium respectively were calculated 
at the percentage of current decreased at the end of the 200 ms test pulse.
Statistical analysis. Data are presented as means ± S.E.M. Unpaired, two-tailed Student’s t-test was used to 
compare the means; p < 0.05 was considered significant.
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